Imatinib mesylate noncompliance simulating chronic myeloid leukemia resistance

被引：7

作者：

Sandoval, C ^{[1
]}

Giamelli, J ^{[1
]}

Jayabose, S ^{[1
]}

机构：

[1] New York Med Coll, Valhalla, NY 10595 USA

来源：

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | 2003年 / 25卷 / 06期

关键词：

D O I：

10.1097/00043426-200306000-00017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：507 / 508

页数：2

共 6 条

[1] High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Grigg, A ;

Arthur, C ;

Taylor, K ;

Herrmann, R ;

Lynch, KP ;

Hughes, TP .

BLOOD, 2002, 99 (09) :3472-3475

[2] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].

Druker, BJ ;

Talpaz, M ;

Resta, DJ ;

Peng, B ;

Buchdunger, E ;

Ford, JM ;

Lydon, NB ;

Kantarjian, H ;

Capdeville, R ;

Ohno-Jones, S ;

Sawyers, CL .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037

[3] Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. [J].

Kantarjian, H ;

Sawyers, C ;

Hochhaus, A ;

Guilhot, F ;

Schiffer, C ;

Gambacorti-Passerini, C ;

Niederwieser, D ;

Resta, D ;

Capdeville, R ;

Zoellner, U ;

Talpaz, M ;

Druker, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) :645-652

[4]

Kreil S, 2001, BLOOD, V98, p435A

[5]

TEBBI CK, 1986, CANCER, V58, P1179, DOI 10.1002/1097-0142(19860901)58:5<1179::AID-CNCR2820580534>3.0.CO

[6]

2-E

← 1 →